Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 3
2017 2
2018 1
2019 3
2020 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr WR, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M. Panagiota V, et al. Among authors: mies a. Am J Hematol. 2021 Jun 1;96(6):E207-E210. doi: 10.1002/ajh.26162. Epub 2021 Apr 7. Am J Hematol. 2021. PMID: 33725366 Free article. No abstract available.
Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes.
Herbig M, Jacobi A, Wobus M, Weidner H, Mies A, Kräter M, Otto O, Thiede C, Weickert MT, Götze KS, Rauner M, Hofbauer LC, Bornhäuser M, Guck J, Ader M, Platzbecker U, Balaian E. Herbig M, et al. Among authors: mies a. Sci Rep. 2022 Jan 18;12(1):870. doi: 10.1038/s41598-022-04939-z. Sci Rep. 2022. PMID: 35042906 Free PMC article.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L. Kubasch AS, et al. Among authors: mies a. Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7. Leukemia. 2022. PMID: 36071100 Free PMC article.
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U. Francke S, et al. Among authors: mies a. Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23. Leuk Lymphoma. 2017. PMID: 27659716 No abstract available.
13 results